Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 14/20 | 0.61 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509138 | 0.78 | CHEK1 (0.46) | TYMSEGFRCHEK1CA5AKDM4E | |
| SCHEMBL1367742 | 0.78 | TYMS (0.61) | TYMSEGFRCHEK1 | |
| SCHEMBL30588970 | 0.78 | TYMS (0.61) | TYMSEGFRCHEK1 | |
| SCHEMBL12620146 | 0.76 | TYMS (0.60) | TYMS | |
| SCHEMBL16009388 | 0.73 | EGFR (0.60) | TYMSEGFRCA5AKDM4EALDH1A1 | |
| SCHEMBL103993 | 0.73 | ALDH1A1 (0.53) | TYMSQTRT1CHEK1CA5AKDM4E | |
| SCHEMBL6647619 | 0.72 | TYMS (1.00) | TYMSQTRT1LMNAPOLBMAPT | |
| SCHEMBL1923985 | 0.72 | EGFR (0.63) | TYMSEGFRCA5AKDM4EALDH1A1 | |
| SCHEMBL3123673 | 0.72 | PARP1 (0.50) | EGFRCHEK1KDM4EALDH1A1LMNA | |
| SCHEMBL30588977 | 0.72 | PARP1 (0.50) | EGFRCHEK1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-17 | — | — | US | disclosed |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-09 | — | — | US | disclosed |
| EP-2310014-B1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | UNIV HOLY GHOST DUQUESNE (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-01-16 | — | — | US | disclosed |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-11-05 | — | — | US | disclosed |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-09-17 | — | — | US | disclosed |
| US-9987283-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-05-10 | — | — | US | disclosed |
| US-9802955-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2017-08-31 | — | — | US | disclosed |
| US-9045489-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-04-18 | — | — | US | disclosed |
| US-8309564-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2011-12-01 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | TYMS 54/4885QTRT1 436/4885EGFR 3072/4885 |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | PLK1, AURKC, TOP1 | TYMS 26/4885QTRT1 333/4885EGFR 3430/4885 |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | TYMS 54/4885QTRT1 436/4885EGFR 3072/4885 |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | PLK1, AURKC, TOP1 | TYMS 26/4885QTRT1 333/4885EGFR 3430/4885 |
| US-20180127434-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHOD OF USE THEREOF | ABCG2, ABCC1, ABCB1 | TYMS 49/4885QTRT1 437/4885EGFR 3276/4885 |
| US-20130096146-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCC1, ABCB1 | TYMS 54/4885QTRT1 436/4885EGFR 3072/4885 |
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCB1, ABCG2 | TYMS 102/4885QTRT1 536/4885EGFR 2114/4885 |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCG2, TP53 | TYMS 89/4885QTRT1 566/4885EGFR 3140/4885 |
| US-20110295002-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | TYMS 54/4885QTRT1 436/4885EGFR 3072/4885 |
| US-20170246170-A1 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCC1, ABCG2, TP53 | TYMS 89/4885QTRT1 566/4885EGFR 3140/4885 |
| US-10414777-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof | ABCG2, ABCC1, ABCB1 | TYMS 49/4885QTRT1 437/4885EGFR 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.